FDA Approves Olutasidenib for Relapsed or Refractory AML with a Susceptible IDH1 Mutation

For more information read the FDA announcement and the Rigel announcement.

For more information read the FDA announcement and the Rigel announcement.

Upcoming Events

Virtual Oncology Reimbursement Meeting (ORM) | Winter 2026

Virtual Oncology Reimbursement Meeting (ORM) | Winter 2026

Virtual December 9, 2026 at 11:00 AM EST
2027 ACCC Leadership Summit

2027 ACCC Leadership Summit

In Person April 22, 2027 at 6:00 PM EDTWillard InterContinental Hotel, 1401 Pennsylvania Avenue Northwest, Washington, DC, USAWashington